A retrospective study evaluating effect of natural history of melanoma on response rate in advanced melanoma patients treated with nivolumab and pembrolizumab.
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Dec 2016 New trial record
- 11 Oct 2016 Results assessing correlation between natural history of melanoma and response rate presented at the 41st European Society for Medical Oncology Congress